Targeting oncostatin M in the treatment of rheumatoid arthritis

  • Theresa C. Barnes
  • Robert J. Moots
Part of the Progress in Inflammation Research book series (PIR)


Oncostatin M (OSM) is a pleiotropic cytokine with potential utility as a treatment for inflammatory arthritis. This pro-inflammatory cytokine is increased in the rheumatoid but not in the osteoarthritic joint. Strategies to block the actions of OSM for use in inflammatory arthritis are being developed and these show significant promise in murine models of disease. Targeting OSM may have a beneficial effect by inhibiting some of the mechanisms of joint destruction in rheumatoid arthritis, which may limit long-term disability in patients. The challenge now is to convert this potential into firm compounds that can be tested in the clinic.


Rheumatoid Arthritis Synovial Fluid Leukaemia Inhibitory Factor Inflammatory Arthritis Adenoviral Gene Transfer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Li WQ, Dehnade F, Zafarullah M (2001) Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires janus kinase/STAT signalling pathway. J Immunol 166: 3491–3498PubMedGoogle Scholar
  2. 2.
    Cross A, Edwards SW, Bucknall R, Moots RJ (2004) Secretion of oncostatin M by neutrophils in rheumatoid arthritis. Arthritis Rheum 50: 1430–1436PubMedCrossRefGoogle Scholar
  3. 3.
    Wahl AF, Wallace PM (2001) Oncostatin M in the anti-inflammatory response. Ann Rheum Dis 60: 75–80Google Scholar
  4. 4.
    Modur V, Feldhaus MJ, Weyrich AS, Jicha DL, Prescott SM, Zimmerman GA, McIntyre TM (1997) Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J Clin Invest 100: 158–168PubMedCrossRefGoogle Scholar
  5. 5.
    Brown TJ, Lioubin MN, Marquardt H (1987) Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes: Synergistic antiproliferative activity of transforming growth factor β1, interferon γ and oncostatin M for human melanoma cells. J Immunol 139: 2977–2983PubMedGoogle Scholar
  6. 6.
    Zarling JM, Shoyab M, Marquardt H, Hanson MB, Lioubin N, Todard GJ (1986) Oncostatin M: A growth regulator produced by differentiated histiocyte lymphoma cells. Proc Natl Acad Sci USA 83: 9739–9743PubMedCrossRefGoogle Scholar
  7. 7.
    Cawston TE, Curry VA, Summers CA, Clark IM, Riley GP, Life PF, Spaull JR, Goldring MB, Koshy PJT, Rowan AD, Shingleton WD (1998) The role of oncostatin M in animal and human connective tissue collagen turnover and its localisation within the rheumatoid joint. Arthritis Rheum 41: 1760–1771PubMedCrossRefGoogle Scholar
  8. 8.
    Mohr W, Menninger H (1980) Polymorphonuclear granulocytes at the pannus-cartilage junction in rheumatoid arthritis. Arthritis Rheum 23: 1413–1414PubMedCrossRefGoogle Scholar
  9. 9.
    Hui W, Bell M, Carroll G (1996) Oncostatin M (OSM) stimulates resorption and inhibits synthesis of proteoglycan in porcine articular cartilage explants. Cytokine 8: 495–500PubMedCrossRefGoogle Scholar
  10. 10.
    Hui W, Bell M, Carroll G (1997) Detection of oncostatin M in synovial fluid from patients with rheumatoid arthritis. Ann Rheum Dis 56: 184–187PubMedCrossRefGoogle Scholar
  11. 11.
    Manicourt DH, Poilvache P, van Egeren A, Devogelaer JP, Lenz ME, Thonar EJMA (2000) Synovial fluid levels of tumor necrosis factor a and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthritis Rheum 43: 281–288PubMedCrossRefGoogle Scholar
  12. 12.
    Clark IM, Powell LK, Ramsay S, Hazleman BL, Cawston TE (1993) The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 36: 372–379PubMedCrossRefGoogle Scholar
  13. 13.
    Ishiguro N, Ito T, Obata K, Fujimoto N, Iwata H (1996) Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. J Rheumatol 23: 1599–1604PubMedGoogle Scholar
  14. 14.
    Tetlow LC, Woolley DE (1998) Comparative immunolocalization studies of collagenase 1 and collagenase 3 production in the rheumatoid lesion, and by human chondrocytes and synoviocytes in vitro. Br J Rheumatol 37: 64–70PubMedCrossRefGoogle Scholar
  15. 15.
    Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, Okada Y (2000) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 59: 455–461PubMedCrossRefGoogle Scholar
  16. 16.
    Cunnane G, Fitzgerald O, Beeton C, Cawston TE, Bresnihan B (2001) Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum 44: 2263–2274PubMedCrossRefGoogle Scholar
  17. 17.
    MacNaul KL, Chartrain N, Kark M, Tocci MJ, Hutchinson NI (1990) Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. J Biol Chem 265: 17238–17345PubMedGoogle Scholar
  18. 18.
    Shingleton WD, Jones D, Xu X, Cawston TE, Rowan AD (2006) Retinoic acid and oncostatin M combine to promote cartilage degradation via matrix metalloproteinase-13 expression in bovine but not human chondrocytes. Rheumatology 45: 958–965PubMedCrossRefGoogle Scholar
  19. 19.
    Fearon U, Mullan R, Markham T, Connolly M, Sullivan S, Poole AR, Fitzgerald O, Bresnihan B, Veale DJ (2006) Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis Rheum 54: 3152–3162PubMedCrossRefGoogle Scholar
  20. 20.
    Bell MC, Carroll GJ, Chapman HM, Mills JN, Hui Wang (1999) Oncostatin M induces leukocyte infiltration and cartilage proteoglycan degradation in vivo in goat joints. Arthritis Rheum 42: 2543–2551PubMedCrossRefGoogle Scholar
  21. 21.
    Hui Wang, Cawston TE, Richards CD, Rowan AD (2005) A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL. Arthritis Res Ther 7: R57–R64PubMedCrossRefGoogle Scholar
  22. 22.
    Rowan AD, Hui Wang, Cawston TE, Richards CD (2003) Adenoviral gene transfer of interleukin-1 in combination with oncostatin M induces significant joint damage in a murine model. Am J Pathol 162: 1975–1984PubMedGoogle Scholar
  23. 23.
    Hui W, Rowan AD, Richards CD, Cawston TE (2003) Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum 48: 3404–3418PubMedCrossRefGoogle Scholar
  24. 24.
    Langdon C, Kerr C, Hassen M, Hara T, Arsenault AL, Richards CD (2000) Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo. Am J Pathol 157: 1187–1196PubMedGoogle Scholar
  25. 25.
    Plater-Zyberk C, Buckton J, Thompson S, Spaull J, Zanders E, Papworth J, Life PF (2001) Amelioration of arthritis in two murine models using antibodies to oncostatin M. Arthritis Rheum 44: 2697–2702PubMedCrossRefGoogle Scholar
  26. 26.
    Wallace PM, MacMaster JF, Rouleau KA, Brown TJ, Loy JK, Donaldson KL, Wahl AF (1999) Regulation of inflammatory responses by oncostatin M. J Immunol 162: 5547–5555PubMedGoogle Scholar
  27. 27.
    Ichihara M, Hara T, Kim H, Murate T, Miyajima A (1997) Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice. Blood 90: 165–173PubMedGoogle Scholar
  28. 28.
    Rhodes A, Deakin A, Spaull J, Coomber B, Aitken A, Life P, Rees S (2000) The generation and characterisation of antagonist RNA aptamers to human oncostatin M. J Biol Chem 275: 28555–28561PubMedCrossRefGoogle Scholar
  29. 29.
    Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1–20PubMedCrossRefGoogle Scholar
  30. 30.
    Malik N, Kallestad JC, Gunderson NL, Austin SD, Neubauer MG, Ochs V, Marquardt H, Zarling JM, Shoyab M, Wei CM et al (1989) Molecular cloning, sequence analysis and functional expression of a novel growth regulator oncostatin M. Mol Cell Biol 9: 2847–53PubMedGoogle Scholar
  31. 31.
    Brown TJ, Rowe JM, Liu JW, Shoyab M (1991) Regulation of IL-6 expression by oncostatin M. J Immunol 147: 2175–80PubMedGoogle Scholar
  32. 32.
    Hamilton JA, Leizer T, Piccoli DS, Royston KM, Butler DM, Croatto M (1991) Oncostatin M stimulates urokinase-type plasminogen activator activity in human synovial fibroblasts. Biochem Biophys Res Commun 180(2): 652–9PubMedCrossRefGoogle Scholar
  33. 33.
    Richards CD, Brown TJ, Shoyab M, Baumann H, Gauldie J (1992) Recombinant oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes in vitro. J Immunol 148: 1731–6PubMedGoogle Scholar
  34. 34.
    Richards CD, Shoyab M, Brown TJ, Gauldie J (1993) Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture. J Immunol 150: 5596–603PubMedGoogle Scholar
  35. 35.
    Yao L, Pan J, Setiadi H, Patel KD, McEver RP (1996) Interleukin 4 or oncostatin M induces a prolonged increase in P-selectin mRNA and protein in human endothelial cells. J Exp Med 184: 81–92PubMedCrossRefGoogle Scholar
  36. 36.
    Richards CD, Langdon C, Deschamps P, Pennica D, Shaughnessy SG (2000) Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. Cytokine 12: 613–21PubMedCrossRefGoogle Scholar
  37. 37.
    Kerfoot SM, Raharjo E, Ho M, Kaur J, Serirom S, McCafferty DM, Burns AR, Patel KD, Kubes P (2001) Exclusive neutrophil recruitment with oncostatin M in a human system. Am J Pathol 159: 1531–9PubMedGoogle Scholar
  38. 38.
    De Hooge AS, van de Loo FA, Bennink MB, de Jong DS, Arntz OJ, Lubberts E, Richards CD, van den Berg WB (2002) Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand. Am J Pathol 160: 1733–43PubMedGoogle Scholar
  39. 39.
    Palmqvist P, Persson E, Conaway HH, Lerner UH (2002) IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol 169: 3353–62PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2009

Authors and Affiliations

  • Theresa C. Barnes
    • 1
  • Robert J. Moots
    • 1
  1. 1.Division of Inflammation, School of Clinical SciencesUniversity of Liverpool, University Hospital AintreeLiverpoolUK

Personalised recommendations